Compare DPRO & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DPRO | CERS |
|---|---|---|
| Founded | 1998 | 1991 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Aerospace | EDP Services |
| Sector | Industrials | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 230.7M | 276.0M |
| IPO Year | 2019 | 1996 |
| Metric | DPRO | CERS |
|---|---|---|
| Price | $6.90 | $2.28 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $15.67 | N/A |
| AVG Volume (30 Days) | ★ 1.6M | 1.3M |
| Earning Date | 01-01-0001 | 05-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 27.27 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $51,326,000.00 |
| Revenue This Year | $42.16 | $25.31 |
| Revenue Next Year | $145.52 | $9.50 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 30.68 |
| 52 Week Low | $1.63 | $1.12 |
| 52 Week High | $14.37 | $2.96 |
| Indicator | DPRO | CERS |
|---|---|---|
| Relative Strength Index (RSI) | 43.90 | 45.25 |
| Support Level | $6.28 | $1.99 |
| Resistance Level | $7.15 | $2.26 |
| Average True Range (ATR) | 0.60 | 0.18 |
| MACD | -0.04 | -0.02 |
| Stochastic Oscillator | 19.08 | 43.75 |
Draganfly Inc is a Canada based company. It is engaged in the provision of engineering services and the manufacture of commercial unmanned vehicle systems and software. The company operates in Canada, the United States, and Internationally. The three segments are Drones, Vital (Vital Intelligence), and Corporate. The Drones segment derives its revenue from products and services related to the sale of unmanned aerial vehicles (UAV). The Vital segment derives its revenue from the sale of products that measure vitals to help detect symptoms from large groups of people from a distance. The Corporate segment includes all costs not directly associated with the Drone and Vital segments. It generates majority of its revenue from Drones segment.
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.